Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

NCT03263637 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Haematological Malignancies Including
Acute Myeloid Leukemia
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
High Risk Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Richter's Syndrome
B-cell Non-Hodgkin Lymphoma
T-cell Non-Hodgkin Lymphoma
Small Lymphocytic Lymphoma
Multiple Myeloma

Interventions

DRUG: AZD4573

Sponsor

AstraZeneca